Description
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, antioxidative, anticancer, anti-angiogenic, and chemopreventive activities. Etoricoxib inhibits COX-2; it also increases activity of superoxide dismutase, catalase, glutathione reductase, and glutathione transferase in animal models. Etoricoxib downregulates expression of matrix metalloproteinases 2 and 9 (MMP2/9), COX-2, MPC-1, VEGF, and MIP-1β in vivo. In other animal models, etoricoxib decreases aberrant crypt foci and lesion formation, suppressing colon carcinogenesis.
References
Nadda N, Vaish V, Setia S, et al. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012 Sep;66(6):474-83. PMID: 22681911.
Sharma P, Kaur J, Sanyal SN. Effect of etoricoxib, a cyclooxygenase-2 selective inhibitor on aberrant crypt formation and apoptosis in 1,2 dimethyl hydrazine induced colon carcinogenesis in rat model. Nutr Hosp. 2010 Jan-Feb;25(1):39-48. PMID: 20204254.
Kanwar SS, Vaiphei K, Nehru B, et al. Antioxidative effects of nonsteroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats. J Environ Pathol Toxicol Oncol. 2008;27(2):89-100. PMID: 18540845.